Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Miconazole is a synthetic imidazole antifungal agent used to treat a variety of fungal infections, including those affecting the skin (such as athlete's foot, jock itch, and ringworm), vagina (vulvovaginal candidiasis), and mouth (oropharyngeal candidiasis)[1][2][3][4][5]. It is available in multiple topical and intravaginal formulations. Miconazole acts primarily by inhibiting the fungal enzyme 14α-lanosterol demethylase, a key component of the CYP450 complex. This inhibition disrupts ergosterol synthesis, leading to altered cell membrane composition and increased permeability, which results in leakage of cellular contents and ultimately inhibits fungal growth[3][5][6]. Miconazole also exhibits some activity against Gram-positive bacteria[3]. The drug was first synthesized in 1969 and received FDA approval in 1974. It is minimally absorbed systemically when applied topically but can be absorbed through mucosal surfaces[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miconazole.